Pharmacogenomics and the Biology of Race
By Myles Jackson,
The Huffington Post
| 01. 05. 2015
The numerous and impassioned responses to Nicholas Wade's recently published Troublesome Inheritance: Genes, Race and Human History have once again reminded us of the complexity, ambiguity and perils of writing about the biology of race. In the US one is reminded of the collective sins of our past, including the eugenics movement of the early twentieth century, whereby a disproportionate percentage of people of color and those from lower socio-economic classes were sterilized, and the Tuskegee Study conducted between 1932 and 1972 in which 600 African-American sharecroppers in rural Alabama were purposely not treated for syphilis in order to ascertain information on the long-term effects of the disease. More recently, debates about the biology of race have raged among certain academic circles. While biologists will tell you that humans (other than identical twins, triplets, etc.) do differ from one another genetically -- i.e. at the level of the DNA, they will also admit that the difference is rather small. And many (but certainly not all) are loath to label populations, which share the same genetic alleles (or different versions of...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...